TOPLINE:Patients with cancer who receive immune checkpoint inhibitors (ICIs) have more than twice the risk for developing psoriasis compared with those who receive other treatments.
METHODOLOGY:Researchers conducted a nationwide cohort study using data from the Taiwan National Health Insurance database and the Taiwan Cancer Registry.A total of 135,230 patients with clinical stage III or IV cancer (mean age, 62.94 years; 45.1% women) who received antineoplastic medications between January 2019 and June 2021 were included in the study.Patients were classified as ICI users (n=3188) and those who received chemotherapy or targeted therapies were classified as non-ICI users (n=132,042).The primary outcome was the incidence of psoriasis during the follow-up period. The mean follow-up duration was 1.46 years.TAKEAWAY:A total of 295 patients (0.2%) were diagnosed with psoriasis. ICI users experienced a higher incidence of psoriasis than non-ICI users (5.76 vs 1.44 cases per 1000 person-years).Those treated with ICIs had more than a threefold increase in the risk for psoriasis after adjusting for demographic factors and comorbidities (hazard ratio [HR], 3.31; P <.001 and more than a twofold risk after further adjusting for death as competing p treated with icis also showed higher psoriasis compared those chemotherapy monoclonal antibodies protease inhibitors adjustments.in practice: nationwide cohort study demonstrated that patients cancer receiving had of developing to or targeted therapy. although this adverse effect is relatively uncommon it important medical professionals clinicians caregivers be aware potential improve skin health ensure optimal care the authors wrote. source:the was led by sheng-yin rph national defense center taipei taiwan. published online on november in jama dermatology. limitations:the lacked data lifestyle genetic factors body mass index environmental exposures which may have influenced incidence psoriasis. additionally claims database did not provide information area severity preventing assessment severity. results applicable only using programmed cell pd-1 ligand-1 taiwan insurance does cover cytotoxic t-lymphocyte protein inhibitors. disclosures:the supported ministry science technology tri-service general hospital one author reported research funding from iqvia outside submitted work. article created several editorial tools including ai part process. human editors reviewed content before publication.>
Source : Medscape